Area of research
Hematology · Oncology
Research interest
Research interests include Multiple Myeloma Research and Treatments, CAR-T cell therapy research, Protein Degradation and Inhibitors, and Immunotherapy and Immune Responses.
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Intrathecal chemotherapy for ciltacabtagene autoleucel–associated movement and neurocognitive toxicity
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Optimization of older adults by a geriatric assessment–guided multidisciplinary clinic before CAR T-cell therapy
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
Measurable Residual Disease and Decision-Making in Multiple Myeloma
Germline predisposition in multiple myeloma
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).
Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma
Additional file 3 of Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma
Recommendations for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis
Sex differences in outcomes in multiple myeloma
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults
Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia
Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer